ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag policy ecology nih cancer

Controversy Mounts Over Gene Patenting Policy
Scott Veggeberg | Apr 26, 1992 | 5 min read
Scientists in industry and academia foresee trouble as NIH persists in claiming ownership over partial sequences Date: April 27, 1992 The reviews from the scientific community remain mostly negative over the National Institutes of Health's patent application for a total of 2,722 partial human gene sequences. Academic researchers, who say they are mostly unaffected by the patenting process, nevertheless are appalled; and while some in the commercial sector of the biotech community now believe
A fruit bat in the hands of a researcher
How an Early Warning Radar Could Prevent Future Pandemics
Amos Zeeberg, Undark | Feb 27, 2023 | 8 min read
Metagenomic sequencing can help detect unknown pathogens, but its widespread use faces challenges.
Letters
The Scientist Staff | Aug 1, 2006 | 5 min read
Restoring natural capital As scientists and practitioners committed to ecological restoration, we found the analogy you made in your April issue1 between restoring natural capital (RNC)2 and new forms of cancer treatment3 to be an extremely powerful one. To a certain degree, RNC and ecological restoration in general, are indeed related to ecosystem degradation in the way that tumor ecology-based treatments are related to traditional cancer therapies, e.g., combined
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Contributors
The Scientist Staff | Jan 1, 2008 | 2 min read
F. Stuart Chapin III, known as Terry, has been a professor of ecology at the University of Alaska Fairbanks since 1973. He studies the effects of changes in climate and wildfire on Alaskan ecology, with a particular focus on developing sustainable ecosystems and human communities. In this issue, Chapin introduces a five-part feature on the effects of climate change on the biosphere. "Scientific assessments now clearly demonstrate the ecological and societal consequences of huma
NIH to Scientists: Get Grant Requests in Soon
Ted Agres | Jan 12, 2003 | 5 min read
Courtesy of CDC/Larry Stauffer HIGH-PRIORITY KILLERS: NIH welcomes proposals to study vaccines and treatments for these and other pathogens. Memo to life scientists who want to take advantage of new research funding for bioterrorism and biodefense: Submit your federal grant applications now, even though the US government's fiscal year 2003 budget is still up in the air. "Investigators should not hesitate to put in applications for grants or respond to RFPs [Request for Proposals] and con
Alternative Medicines
The Scientist | Jul 1, 2012 | 10+ min read
As nonconventional medical treatments become increasingly mainstream, we take a look at the science behind some of the most popular.
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard
What Budget Cuts Might Mean for US Science
Diana Kwon | Mar 21, 2017 | 5 min read
A look at the historical effects of downsized research funding suggests that the Trump administration’s proposed budget could hit early-career scientists the hardest.  
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.

Run a Search

ADVERTISEMENT